Quantum meets Biotech
Day: Monday 20 October
Time: 9.30am – 12.30pm
Venue: Science Gallery Melbourne, Parkville VIC
Quantum technology is poised to transform biotech, from accelerating drug discovery and development to revolutionising diagnostics and unlocking the promise of personalised medicine.
At Quantum Meets Biotech, some of Australia’s most innovative quantum companies and researchers will pitch their cutting-edge solutions to a panel of leading biopharma experts and investors.
Expect rapid-fire presentations, fresh ideas, and real-world insights on market opportunities, customer needs, and the path from concept to commercial success.
Join us to get involved in the collision of two frontier industries – and help shape the next big wave in healthcare innovation.
Enquiries: Olivia Dennis
FocalPoint by Tenmile
Day: Monday 20 October
Time: 12.30pm – 6.00pm
Venue: Science Gallery Melbourne, Parkville VIC
After the roaring success of our 2024 event in Sydney, Tenmile is excited to be bringing back for a second year our health innovation research and investment forum – FocalPoint. FocalPoint will again bring together a curated group of Australia’s best minds in health and biotech, from all parts of our vibrant ecosystem, along with select global investors and innovators. This year, hosted in Melbourne immediately prior to Australia’s premier biotech industry conference, AusBiotech.
As a refresher – FocalPoint is an Australian premier health innovation and investment forum, bringing together a curated group of Australian leaders in health and life sciences alongside global experts. Last year, our inaugural event featured Reed Jobs, from Yosemite Ventures and Alice Zhang, CEO of Verge Genomics, both from the US, amongst a host of other incredible Australian innovators. Followed by a networking event with +350 people from across the ecosystem.
This year is set to be as equally exciting and inspiring as our previous events – with a host of new topics and innovators being showcased from Australia, the US and beyond.
Here’s a taste of the agenda for this year:
- Keynote from Ben Liu, CEO of Formation Bio – an AI-native, tech-driven pharma company that acquires clinical-stage drug assets and accelerates their development using proprietary AI and software platforms to streamline clinical trials and drug development.
- Fireside chat with Laura Shawver, CEO of Capstan Therapeutics – a clinical-stage biotech pioneering in vivo CAR-T therapy via targeted lipid nanoparticles (tLNPs) delivering anti-CD19 mRNA directly to T-cells, now acquired by AbbVie to advance treatments for B-cell-mediated autoimmune diseases.
- In conversation with Dr John McHutchinson – CEO & Chairman, Tune Therapeutics – a biotechnology company developing a precision “genetic tuning” platform called TEMPO that modulates gene networks epigenetically—without altering DNA sequences—to treat complex diseases.
A panel discussing neuro drug development with presentations from leading Australian and US companies and researchers
Research showcase covering AMR, BCI, Melanoma & Non-opioid pain solutions
Tenmile’s FocalPoint will be followed by the Healthtech Muster, an ecosystem networking and celebration event we’re hosting in partnership with Brandon Capital.
Enquiries: Kelsee Sewell
The Healthtech Muster: By Tenmile & Brandon Capital
Day: Monday 20 October
Time: 6.00pm – late
Venue: Great Room, W Melbourne
The Healthtech Muster is Australia’s ultimate health innovation party – uniting founders, investors, researchers, and industry leaders for a high-energy night of connection, conversation, and celebration. To kick off Australia’s biggest week in biotech in style, we’re taking over the Great Room at W Melbourne on the eve of AusBiotech 2025 with great food and drinks, brilliant company, exclusive networking, and door prizes from R.M.Williams & Akubra – all in one unforgettable evening.
Expect rapid-fire presentations, fresh ideas, and real-world insights on market opportunities, customer needs, and the path from concept to commercial success.
Join us to get involved in the collision of two frontier industries – and help shape the next big wave in healthcare innovation.
Supporters of the event: Tenmile, Brandon Capital, Brandon BioCatalyst, Prime Financial Group, What the Health, Radium Capital, R.M.Williams, Akubra
Enquiries: Kelsee Sewell
A Fine Balance - How to handle a dilemma of priorities in Early Phase Oncology
Day: Thursday 23 October
Time: 7.00am – 8.30am
Venue: Melbourne Convention & Exhibition Centre
Running Early Phase Oncology Clinical Trials is a balancing act that can be complex and challenging, even when things go right. A lot of factors, such as budget and resource availability, changes in regulatory guidelines and an ever-shifting treatment landscape, can impact how aggressive drug developers are in pushing through their early phase studies. In this panel discussion we will examine how to maximise the value of Early Phase Oncology studies whilst balancing cost and resource constraints all while keeping patients at the forefront.
Registration: Invitation only. For more details please contact Audrey Comparet or Bryce Davies.
Practical Application of New Approach Methodologies (NAMs) to support First-In-Human (FIH) Clinical Trials: Strategies, Challenges, and Regulatory Perspectives
Day: Friday 24 October
Time: 7.30am – 9.30am
Venue: Melbourne Convention & Exhibition Centre
With the release of a Roadmap to reduce animal testing in preclinical safety studies by the FDA in April 2025 and the EMA’s release of the Reflection paper on the current regulatory testing requirements for human medicinal products and opportunities for implementation of the 3Rs for consultation in February 2025, there is an urgent need to develop, validate and understand the place of New Approach Methodologies (NAMs) in the drug development paradigm.
Human Research Ethics Committees (HRECs) oversee First-In-Human (FIH) trials and are responsible for ensuring both the ethical acceptability and the scientific integrity of human research. HRECs also need to remain aware of regulatory changes driving innovation in the nonclinical development of new medicines. This workshop will provide participants with initial skills in examining NAMs as supportive methods for FIH clinical studies.
Registration Details: invitation only. For enquiries please contact Leanne Weekes, Bellberry.